The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial
Open accessAbstract
Hepatic encephalopathy (HE) can cause major morbidity despite standard of care (SOC; rifaximin/lactulose). Fecal microbial transplant (FMT) enemas postantibiotics are safe, but the effect of FMT without antibiotics using the capsular route requires investigation. The aim of this work was to determine the safety, tolerability, and impact on mucosal/stool microbiota and brain function in HE after capsular FMT in a randomized, single‐blind, placebo‐controlled clinical trial in Virginia. Patients with cirrhosis with recurrent HE with MELD (Model for End‐Stage Liver Disease) <17 on SOC were randomized 1:1 into receiving 15 FMT capsules versus placebo from a single donor enriched in Lachnospiraceae and Ruminococcaceae. Endoscopies with duodenal and sigmoid biopsies, stool analysis, cognition, serum lipopolysaccharide‐binding protein (LBP), and duodenal antimicrobial peptide (AMP) expression at baseline were used. Clinical follow‐up with SOC maintenance was performed until 5 months. FMT‐assigned patients underwent repeat endoscopies 4 weeks postenrollment. Twenty subjects on lactulose/rifaximin were randomized 1:1. MELD score was similar at baseline (9.6 vs. 10.2) and study end (10.2 vs. 10.5). Six patients in the placebo group required hospitalizations compared to 1 in FMT, which was deemed unrelated to FMT. Infection/HE episodes were similar between groups. Baseline microbial diversity was similar in all tissues between groups. Post‐FMT, duodenal mucosal diversity (P = 0.01) increased with higher Ruminococcaceae and Bifidobacteriaceae and lower Streptococcaceae and Veillonellaceae. Reduction in Veillonellaceae were noted post‐FMT in sigmoid (P = 0.04) and stool (P = 0.05). Duodenal E‐cadherin (P = 0.03) and defensin alpha 5 (P = 0.03) increased whereas interleukin‐6 (P = 0.02) and serum LBP (P = 0.009) reduced post‐FMT. EncephalApp performance improved post‐FMT only (P = 0.02). Conclusion: In this phase 1 study, oral FMT capsules are safe and well tolerated in patients with cirrhosis and recurrent HE. FMT was associated with improved duodenal mucosal diversity, dysbiosis, and AMP expression, reduced LBP, and improved EncephalApp performance. Further studies are needed to prove efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014) · Hepatology · doi:10.1002/hep.27210 · Cited by 2,056
Self-citationRivière, A., Selak, M., Lantin, D., Leroy, F., & De Vuyst, L. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00979 · Cited by 1,726
Altered profile of human gut microbiome is associated with cirrhosis and its complications
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., Noble, N. A., Unser, A. B., Daita, K., Fisher, A. R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.019 · Cited by 1,099
Self-citationNeuropsychological characterization of hepatic encephalopathy
Weissenborn, K., Ennen, J. C., Schomerus, H., Rückert, N., & Hecker, H. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00026-5 · Cited by 796
Bajaj, J. S., Kassam, Z., Fagan, A., Gavis, E. A., Liu, E., Cox, I. J., Kheradman, R., Heuman, D., Wang, J., Gurry, T., et al. (2017) · Hepatology · doi:10.1002/hep.29306 · Cited by 633
Self-citationUpdate on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Linkage of gut microbiome with cognition in hepatic encephalopathy
Bajaj, J. S., Ridlon, J. M., Hylemon, P. B., Thacker, L. R., Heuman, D. M., Smith, S., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2011 · Cited by 547
Self-citationBajaj, J. S., Hylemon, P. B., Ridlon, J. M., Heuman, D. M., Daita, K., White, M. B., Monteith, P., Noble, N. A., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00152.2012 · Cited by 527
Self-citationHospital readmissions among patients with decompensated cirrhosis
Volk, M. L., Tocco, R. S., Bazick, J., Rakoski, M. O., & Lok, A. S. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.314 · Cited by 451
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430
Targeting the gut-liver axis in liver disease
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S., & Jalan, R. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.007 · Cited by 419
Self-citationCirrhosis, bile acids and gut microbiota: Unraveling a complex relationship
Ridlon, J. M., Alves, J. M., Hylemon, P. B., & Bajaj, J. S. (2013) · Gut Microbes · doi:10.4161/gmic.25723 · Cited by 336
Self-citationPersistence of Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy
Bajaj, J. S., Schubert, C. M., Heuman, D. M., Wade, J. B., Gibson, D. P., Topaz, A., Saeian, K., Hafeezullah, M., Bell, D. E., Sterling, R. K., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.015 · Cited by 302
Self-citationBajaj, J. S., Reddy, K. R., Tandon, P., Wong, F., Kamath, P. S., Garcia‐Tsao, G., Maliakkal, B., Biggins, S. W., Thuluvath, P. J., Fallon, M. B., et al. (2016) · Hepatology · doi:10.1002/hep.28414 · Cited by 234
Self-citationTandon, P., Tangri, N., Thomas, L., Zenith, L., Shaikh, T., Carbonneau, M., Ma, M., Bailey, R. J., Jayakumar, S., Burak, K. W., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.303 · Cited by 207
Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology
Chen, Y., Ji, F., Guo, J., Shi, D., Fang, D., & Li, L. (2016) · Scientific Reports · doi:10.1038/srep34055 · Cited by 205
Tapper, E. B., Halbert, B., & Mellinger, J. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.009 · Cited by 203
Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing
Zhang, Z., Zhai, H., Geng, J., Yu, R., Ren, H., Fan, H., & Shi, P. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.221 · Cited by 188
Allampati, S., Duarte-Rojo, A., Thacker, L. R., Patidar, K. R., White, M. B., Klair, J. S., John, B., Heuman, D. M., Wade, J. B., Flud, C., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.377 · Cited by 181
Self-citationLong-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis
Bajaj, J. S., Fagan, A., Gavis, E. A., Kassam, Z., Sikaroodi, M., & Gillevet, P. M. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.033 · Cited by 181
Self-citationAssimakopoulos, S. F., Tsamandas, A. C., Tsiaoussis, G. I., Karatza, E., Triantos, C., Vagianos, C. E., Spiliopoulou, I., Kaltezioti, V., Charonis, A., Nikolopoulou, V. N., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02609.x · Cited by 165
Bajaj, J. S., Cox, I. J., Betrapally, N. S., Heuman, D. M., Schubert, M. L., Ratneswaran, M., Hylemon, P. B., White, M. B., Daita, K., Noble, N. A., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00268.2014 · Cited by 143
Self-citationMuñoz, L., Borrero, M., Cantera, M., Conde, E., del Campo, R., Rodríguez‐Serrano, M., Lario, M., Sánchez‐Díaz, A., Pastor, Ó., Díaz, D., et al. (2018) · Hepatology · doi:10.1002/hep.30349 · Cited by 140
Paneth cell defects in Crohn’s disease patients promote dysbiosis
Liu, T., Gurram, B., Baldridge, M. T., Head, R. D., Lam, V., Luo, C., Cao, Y., Simpson, P. M., Hayward, M., Holtz, M. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86907 · Cited by 137
Self-citationIntestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature
Pijls, K. E., Jonkers, D. M. A. E., Elamin, E. E., Masclee, A., & Koek, G. H. (2013) · Liver International · doi:10.1111/liv.12271 · Cited by 127
Bajaj, J. S., Acharya, C., Fagan, A., White, M. B., Gavis, E. A., Heuman, D. M., Hylemon, P. B., Fuchs, M. A., Puri, P., Schubert, M. L., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0085-9 · Cited by 124
Self-citationSystemic inflammation and ammonia in hepatic encephalopathy
Tranah, T. H., Vijay, G. K. M., Ryan, J. M., & Shawcross, D. L. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9370-2 · Cited by 117
Kaji, K., Takaya, H., Saikawa, S., Furukawa, M., Sato, S., Kawaratani, H., Kitade, M., Moriya, K., Namisaki, T., Akahane, T., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i47.8355 · Cited by 107
Bajaj, J. S., Betrapally, N. S., Hylemon, P. B., Thacker, L. R., Daita, K., Kang, D. J., White, M. B., Unser, A. B., Fagan, A., Gavis, E. A., et al. (2015) · Scientific Reports · doi:10.1038/srep18559 · Cited by 92
Self-citationCurrent Management of Hepatic Encephalopathy
Acharya, C., & Bajaj, J. S. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0179-4 · Cited by 63
Self-citationPustelny, C., Komor, U., Pawar, V., Lorenz, A., Bielecka, A., Moter, A., Gocht, B., Eckweiler, D., Müsken, M., Grothe, C., et al. (2014) · Infection and Immunity · doi:10.1128/iai.02234-14 · Cited by 50
Lucidi, C., Corradini, S. G., Abraldeṣ, J. G., Merli, M., Tandon, P., Ferri, F., Parlati, L., Lattanzi, B., Poli, E., Gregorio, V. D., et al. (2016) · Liver Transplantation · doi:10.1002/lt.24517 · Cited by 46
Nardelli, S., Allampati, S., Riggio, O., Mullen, K. D., Prakash, R., Gioia, S., Unser, A. B., White, M. B., Fagan, A., Wade, J. B., et al. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4425-6 · Cited by 22
Self-citation
Cited by
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Chopyk, D. M., & Grakoui, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.077 · Cited by 490
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy
Montagnese, S., Rautou, P.-E., Romero-Gómez, M., Larsen, F. S., Shawcross, D. L., Thabut, D., Vilstrup, H., & Weissenborn, K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.001 · Cited by 440
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
Metadata
- Authors
- Bajaj, J. S., Salzman, N. H., Acharya, C., Sterling, R. K., White, M. B., Gavis, E. A., Fagan, A., Hayward, M., Holtz, M. L., Matherly, S., Lee, H., Osman, M., Siddiqui, M. S., Fuchs, M., Puri, P., Sikaroodi, M., & Gillevet, P. M.
- Venue
- Hepatology
- Published
- 2019-06-18
- Volume
- 70
- Issue
- 5
- Pages
- 1690-1703
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2943508390
- Cited by
- 295
- References
- 35
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.